Back to Results
First PageMeta Content
Medicine / Antiretroviral drug / Protease inhibitor / Food and Drug Administration / HIV / Polypharmacy / Norfloxacin / Clinical trial / Pharmaceutical sciences / Pharmacology / Health


21-548S028 Fosamprenavir Clinical BPCA & PREA
Add to Reading List

Open Document

File Size: 1,93 MB

Share Result on Facebook

City

Reference / /

Company

The Health Resources / AEs / Treatment Group / ITT / /

Country

United States / /

Event

FDA Phase / /

Facility

Laboratory Toxicities / Laboratory Findings / /

IndustryTerm

Treatment of HIV / /

MedicalCondition

HIV infection / HIV / Infection / neutropenia / /

MedicalTreatment

Antiretroviral Therapy / /

Organization

FDA / National Institute of Health / Advisory Committee / MD NDA / PDUFA Goal Date Division / /

Person

Review Neil Rellosa / Neil Rellosa / /

Product

Lexiva / age / Lexiva® (fosamprenavir) Oral / S28 / /

PublishedMedium

Baseline / /

Technology

Pharmacokinetics / Pharmacodynamics / /

SocialTag